World Bleeding Disorders Registry
Launched by WORLD FEDERATION OF HEMOPHILIA · Oct 27, 2017
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The World Bleeding Disorders Registry (WBDR) is a global study aimed at understanding hemophilia and related bleeding disorders, including Hemophilia A, Hemophilia B, and Von Willebrand Disease. The goal of this registry is to gather important information about patients’ conditions, treatments, and symptoms, which will help doctors improve care for people with these disorders. If you have hemophilia or von Willebrand Disease and are receiving treatment at one of the participating hemophilia treatment centers, you may be eligible to join this study.
Participants in the WBDR will provide consent for their information to be collected, but this data will be kept anonymous to protect their privacy. There are no exclusions based on age or gender, meaning everyone with these conditions can participate. By joining the registry, you will contribute to a better understanding of hemophilia, which can lead to improved treatments and care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of participating Hemophilia Treatment Centres with Hemophilia A or B, or von Willebrand Disease
- Exclusion Criteria:
- • none
About World Federation Of Hemophilia
The World Federation of Hemophilia (WFH) is a global non-governmental organization dedicated to improving the lives of individuals with hemophilia and related bleeding disorders. Founded in 1963, WFH focuses on advancing care, promoting education, and supporting research initiatives worldwide. Through collaboration with healthcare professionals, patient organizations, and stakeholders, WFH strives to enhance treatment access, foster innovation in clinical practices, and advocate for the rights of those affected by bleeding disorders. The organization's commitment to evidence-based research and clinical trials plays a crucial role in driving advancements in hemophilia care and improving health outcomes for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials